EVMN
Evommune, Inc. · Healthcare
Insiders bought $133K of Evommune, Inc. in the last 12 months
1 insider bought on 1 day.
EVMN over the last year
Largest buyers, last 12 months
EVMN after insider buys
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Every filing
9 insider filings since 2026, newest first
Arthur S Kirsch · Director
Janice Suzann Drew · Chief of Dev. Operations
Jeegar Pravinkumar Patel · Chief Scientific Officer
Luis C. Pena · President and CEO
David E Cohen · Director
Jeegar Pravinkumar Patel · Chief Scientific Officer
Luis C. Pena · President and CEO
Gregory S. Moss · Chief Business & Legal Officer
Kyle Carver · Chief Financial Officer
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.